Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib — boosting late-stage focus
Gilead $GILD and its partners at Galapagos $GLPG picked up some “very impressive” mid-stage data for their star immunology drug filgotinib, which handily beat out a placebo in treating psoriatic arthritis.
Deep into a Phase III program for rheumatoid arthritis, researchers say that the drug collected an ACR20 score of 80% versus 33% for the sugar pill, hitting the primary endpoint. Compare that to Pfizer’s Xeljanz, which was approved for this condition with an ACR20 of 50%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.